.png "ADMA Biologics (NASDAQ: ADMA)")
After WBB Securities and Oppenheimer gave ADMA Biologics (NASDAQ: ADMA) a Buy rating last month, the company received another Buy, this time from Maxim Group. Analyst Jason McCarthy maintained a Buy rating on ADMA Biologics today and set a price target of $12. The company’s shares closed on Friday at $2.95.
McCarthy commented:
“ADMA announced that the company has submitted responses to the FDA for the Complete Response Letter (CRL) related to the BIVIGAM Prior Approval Supplement (PAS). The company anticipates an acknowledgment letter from FDA within 30 days and will provide updates as appropriate on the BIVIGAM PAS review.”
According to TipRanks.com, McCarthy has currently no stars on a ranking scale of 0-5 stars, with an average return of -11.6% and a 23.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
ADMA Biologics has an analyst consensus of Strong Buy, with a price target consensus of $12.20.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.96 and a one-year low of $2.08. Currently, ADMA Biologics has an average volume of 231.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ADMA Biologics, Inc. is a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. It operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate.
